Cencora stock

COR · NYSE · USD

Compare Cencora
$350.56Change from previous close: −1.79%Absolute change: −$6.38

Close · November 17, 2026

Price history

−3.48% over the period

1 year: from $365.00 (November 17, 2025) to $352.31 (November 17, 2026), −3.48%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 2026$352.31
October 30, 2026$330.84
September 30, 2026$300.25
August 31, 2026$323.60
July 31, 2026$311.34
June 30, 2026$282.98
May 29, 2026$269.36
April 30, 2026$308.01
March 31, 2026$314.14
February 27, 2026$372.14
January 30, 2026$359.22
December 31, 2025$337.75
November 28, 2025$368.93
November 17, 2025$365.00

At a glance

  • The company

    Sources and distributes pharmaceuticals, medical supplies and healthcare products to hospitals, pharmacies, clinics and other healthcare providers in the U.S. and internationally

  • Latest results

    Quarter to September 30, 2026 · EPS $4.66 (estimate $4.57)

TickerLandia's take on Cencora

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$244.82
52-wk high$377.54

−7.15% from the 52-week high

Analysts · 14 analysts

Average target$382.42+9.09% vs. price

Buy 10 · Hold 4 · Sell 0 · Buy

TickerLandia Fingerprint: Cencora

Compared with similar companies: strong momentum, low profitability, and low risk.

Financials and price compared with 11 companies in the medical distribution industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Cencora is priced as in the past and cheaper than similar companies

On the latest fiscal year's earnings (2026), Cencora's P/E today is 19.6, in line with the median of its last 9 fiscal years (20.4; between 12.2 and 50.5 from 2017 to 2026). Cencora's P/E (trailing 12 months): 20.0, −29% against the median of a group of 11 similar companies (28.2).

P/E compared with its history

Compared with 11 similar companies

Cencora's metrics compared with similar companies
MetricCencoraPosition in the groupBand
P/E (trailing 12 months)20.0Low
Forward P/E16.4Middle
Operating margin1.4%Low
ROE129.0%High
Debt/equity3.06High

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Cencora. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$88.35B

Latest quarter · Q3 2026

Net income

$519.4M

Latest quarter · Q3 2026

Quarterly net margin

0.6%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$68.11B
P/E
20.0
EPS
$17.85
Volume
1.03M
Daily trading
€437.99M
Dividend yield
0.70%
Last ex-dividend on November 13, 2026

How Cencora is changing

All results
  • Revenue grew 9.5% a year on average over the last 5 years

  • Profits turn into cash: free cash flow equal to 154% of net income

  • Shares outstanding down 6.9% in 5 years

Returns

Cencora returns with dividends

$1,000 invested in Cencora 5 years ago, on November 17, 2021, would be worth $2,998 today with dividends reinvested: +199.76% in total, +24.56% per year. On price alone it would be $2,826 (+182.59%).

PeriodCencoraS&P 500$1,000 becomes
1 month+3.62%−3.17%$1,036
6 months+36.03%+0.11%$1,360
Year to date+4.31%+8.34%$1,043
1 year−2.73%+11.15%$973
3 years+85.12%+64.30%$1,851
5 years+199.76%+58.18%$2,998
10 years+484.88%+239.10%$5,849

Over the last 6 months it has done better than 74% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment

The chart in detail

Cencora: technical analysis

Cencora shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 6.5% below its all-time closing high ($374.75, November 25, 2025).

Trend
No clear trend
RSI (14 sessions)
58
Between 30 and 70
vs 200-session average
+10.71%

Support and resistance

Price areas where Cencora has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$376.45+7.39%3 touches, last on March 2, 2026
  2. Resistance$358.25+2.19%2 touches, last on January 20, 2026
  3. Resistance$350.77+0.06%2 touches, last on January 6, 2026
  4. Last price$350.56
  5. Support$344.09−1.85%2 touches, last on October 15, 2026
  6. Support$335.62−4.26%4 touches, last on September 3, 2026
  7. Support$327.75−6.51%4 touches, last on April 20, 2026

Volatility and risk

Over the last year it has moved little with the S&P 500.

Beta (1 year) vs S&P 500
0.05
Volatility (60 sessions, annualised)
25.6%
Largest fall in the last year
−32.56%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Cencora: seasonality

Average monthly price change over 32 years

+4.6%Jan−0.3%Feb+0.8%Mar+1.8%Apr+1.7%May+2.9%Jun+1.4%Jul−0.8%Aug+2.7%Sep−0.2%Oct+3.4%Nov+1.8%Dec

Over the last 32 years, the strongest month for Cencora has been January: +4.59% on average, positive in 24 years out of 31. The weakest has been August: −0.81% on average, positive in 20 years out of 32. November, the current month, has been positive in 22 years out of 31 (+3.38% on average).

Show chart data
MonthAverageMedianPositive years
January+4.59%+4.79%24 of 31
February−0.34%+0.94%17 of 31
March+0.80%+2.78%18 of 31
April+1.76%+2.00%18 of 31
May+1.70%+1.68%19 of 32
June+2.90%+0.97%18 of 32
July+1.42%+2.40%18 of 32
August−0.81%+0.58%20 of 32
September+2.67%+0.28%17 of 32
October−0.24%+1.71%19 of 32
November+3.38%+6.60%22 of 31
December+1.84%+0.26%17 of 31

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Cencora and its competitors

Operating a network that moves pharmaceuticals on a scale of $337.4 billion in revenue, Cencora sources and distributes drugs in the United States and abroad. Its U.S. business supplies generic and injectable medicines, over-the-counter products and home healthcare equipment to hospitals, retail and mail-order pharmacies, clinics and long-term care providers, and it also handles plasma, blood products and vaccines. Services range from pharmacy management and staffing to clinical trial support, data analytics for drug makers and supply management software. Products for companion and production animals are also part of the offer.

Headquarters
Conshohocken, United States
Employees
47,000
Founded
2001
Chief executive
Robert Mauch
Cencora and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
CencoraCOR$68.11B1.4%20.0+36.03%
Cardinal HealthCAH$64.97B1.3%36.4+43.06%
McKessonMCK$126.04B1.6%28.2+43.53%
Henry ScheinHSIC$9.17B5.8%22.7+14.05%
Sigma HealthcareSIG$22.55B9.2%48.3+3.55%
Sinopharm Group Ltd H1099$6.68B3.0%6.51−3.31%

Same industry or related industries, similar size. Compare Cencora with its competitors · Full profile